Clinical evidence for repurposed generics
Many FDA-approved drugs have been studied for cancer uses beyond their original approved indications. When these drugs go off-patent, the supporting clinical evidence is often left fragmented and difficult to evaluate.
Reboot Rx identifies generic drugs with repurposing potential in cancer, assesses where further study may be warranted, and develops transparent resources to support clinical awareness and informed discussion.
Our online resources for clinicians include:
Summaries and key outcomes from randomized controlled trials, meta-analyses, and observational studies
Safety considerations
Mechanism of action
Information on drug access
Evidence Resources:
5-alpha reductase inhibitors (5-ARIs) in prostate cancer active surveillance
Relevant for: Urologists and other clinicians managing patients with prostate cancer on active surveillance
Aspirin in PI3K-altered stage II–III colorectal cancer
Relevant for: Oncologists and other clinicians treating patients with colorectal cancer
5-ARIs and aspirin are not FDA-approved for prostate cancer or colorectal cancer, respectively.
Reboot Rx surfaces and organizes evidence. Our evidence resources are for informational purposes only and are not intended to provide medical advice.
Contribute Clinical Insight
We're actively expanding to other cancer types where generic drugs show repurposing potential. If you’re interested in drug repurposing, we value clinical input from all specialties.
Share your perspective
We welcome clinical insight on treatment selection, implementation opportunities, and real-world outcomes.
Collaborate
Participate in pilots, real-world data efforts, and health system partnerships.